Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Related Information
Registry Information

Alternate Title

Phase I/II Study of Vandetanib in Young Patients With Hereditary Medullary Thyroid Carcinoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II, Phase I	Biomarker/Laboratory analysis, Treatment	Active	5 to 18	NCI	NCI-07-C-0189 07-C-0189, NCT00514046

Special Category: NCI Web site featured trial, NIH Clinical Center trial

Trial Description

Purpose:

Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

This phase II trial is studying the side effects and best dose of vandetanib and to see how well it works in treating patients with medullary thyroid cancer.

Eligibility:

Eligibility criteria include the following:

• 5-18 years old
• Measurable disease
• No pheochromocytoma
• At least 4 weeks since surgery, chemotherapy, or external beam radiation therapy
• At least 1 month since monoclonal antibodies
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive vandetanib by mouth once a day for as long as benefit is shown.

Blood and previously collected tumor tissue samples will be used for laboratory studies.

After finishing treatment, patients will be evaluated periodically.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

Frank Balis, MD, Principal investigator		Ph: 301-496-0085 Email: balisf@nih.gov

U.S.A.
Maryland
	Bethesda
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
		Clinical Trials Office - Warren Grant Magnusen Clinical Center - NCI Clinical Trials Referral Office	Ph:  888-NCI-1937
Missouri
	Saint Louis
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		Samuel Wells, MD, FACS	Ph:  314 454-1898 800-600-3606

Related Information

Featured trial article

Registry Information
Official Title		Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma
Trial Start Date		2007-06-01
Trial Completion Date		2009-06-01 (estimated)
Registered in ClinicalTrials.gov		NCT00514046
Date Submitted to PDQ		2007-07-11
Information Last Verified		2008-03-30